Australia introduces world-leading prostate cancer screening guidelines for men aged 50-69

Australia has introduced updated 2026 Clinical Guidelines for the Early Detection of Prostate Cancer, the first major overhaul in a decade. Approved by the National Health and Medical Research Council, the guidelines recommend biennial PSA testing for men aged 50 to 69, and from age 45 for high-risk individuals. To minimize overdiagnosis and overtreatment, the framework introduces active surveillance for low-grade cases and mandates MRI scans before biopsies. The federal government is supporting implementation with a $320,000 grant to educate general practitioners.

Prostate cancer screening guidelines overhaul

• ▪The Australian Federal Government provided $320,000 to the Royal Australian College of General Practitioners to develop and implement an education and awareness program for doctors regarding the 2026 prostate cancer screening guidelines.
• ▪The updated 2026 guidelines mandate that general practitioners proactively initiate discussions about Prostate-Specific Antigen (PSA) testing with men, rather than relying on patients to request the test.
• ▪The updated 2026 Clinical Guidelines for the Early Detection of Prostate Cancer were developed by the Prostate Cancer Foundation of Australia in partnership with Cancer Council Australia and approved by the National Health and Medical Research Council.
• ▪The Australian Government released the updated 2026 Clinical Guidelines for the Early Detection of Prostate Cancer in August 2026, marking the first major update to the guidelines in ten years.

Age-based testing recommendations

• ▪Under the 2026 guidelines, men aged 45 to 49 who are not at high risk are not recommended for routine testing, but may be offered an initial Prostate-Specific Antigen (PSA) test if interested in their prostate health.
• ▪The 2026 guidelines recommend that healthy men aged 70 and over continue Prostate-Specific Antigen (PSA) testing every two years if their life expectancy is more than seven years.
• ▪Under the 2026 guidelines, Australian men aged 50 to 69 are recommended to undergo Prostate-Specific Antigen (PSA) testing every two years after an informed discussion with their general practitioner.

High-risk population screening criteria

• ▪High-risk criteria for prostate cancer under the 2026 guidelines include having a brother with prostate cancer, a father diagnosed before age 65, two or more second-degree relatives who died from the disease, a BRCA2 mutation, or Black sub-Saharan ancestry.
• ▪The 2026 guidelines recommend that men at high risk of prostate cancer start Prostate-Specific Antigen (PSA) testing every two years starting from age 45.

MRI-before-biopsy diagnostic pathway

• ▪The 2026 guidelines recommend that men with high Prostate-Specific Antigen (PSA) levels undergo a multiparametric MRI scan before receiving a biopsy to reduce unnecessary and invasive procedures.
• ▪Incorporating MRI scans into the prostate cancer diagnostic work-up aims to decrease the number of required biopsies while ensuring significant cancers are not missed.

Active surveillance for low-grade cancer

• ▪Urological Society of Australia and New Zealand president Damien Bolton noted that more than 80 percent of Australian men with low-grade prostate cancer are monitored closely without treatment to avoid complications like erectile dysfunction and infection.
• ▪The 2026 guidelines recommend for the first time that men with low-grade prostate cancer manage their condition through active surveillance, using regular blood tests and scans instead of immediate surgery or radiation.

Prostate cancer burden in Australia

• ▪Prostate cancer is the most commonly diagnosed cancer in Australian men, with approximately 28,000 to 29,000 new cases diagnosed annually.
• ▪Approximately 4,000 Australian men die from prostate cancer each year, making it the second leading cause of cancer death in Australian men behind lung cancer.
• ▪Australia is a world leader in prostate cancer detection and treatment, with a five-year survival rate for the disease sitting at 95 percent.